Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation

Fig. 4

The MIC distribution of CMS in monotherapy or combination with FOS against 136 KPC-producing Klebsiella pneumoniae, and probability of target attainment (PTA) of 60 AUC24/MIC for TGC dosing regimens in critically ill elderly patients with normal renal function (Left) and renal impairment (right). The dotted line indicates the PTA of 0.9. FOS, fosfomycin; CST, colistin; CMS, colistin methanesulfonate; MIU, million IU

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us